Tazemetostat

(Tazverik)

Tazemetostat

Drug updated on 11/15/2023

Dosage FormTablet (oral; 200 mg)
Drug ClassMethyltransferase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
  • Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.